No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
OGN240816C17500
- 3.90
- +0.30+8.33%
15min DelayTrading Jul 22 15:06 ET
3.90High3.60Low
3.60Open3.60Pre Close12 Volume49 Open Interest17.50Strike Price4.49KTurnover0.00%IV0.09%PremiumAug 16, 2024Expiry Date3.88Intrinsic Value100Multiplier25DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma5.63Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Organon (NYSE:OGN) Has No Shortage Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too
S&P 500 Futures Climb In Premarket Trading; Trump Media & Tech, Travelers Lag
This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, Match Group Inc. (MTCH) was up 9.3% in pre-market
Express News | Organon & Co: Expects That It Will Record Approximately $15 Mln of Milestone Expense in Q2 of 2024
Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE:OGN), a global healthcare company with a focus on women's health, will release its second quarter 2024 financial results on August
Express News | NYSE Order Imbalance 104610.0 Shares on Buy Side
Express News | NYSE Order Imbalance 56041.0 Shares on Buy Side
Comments
Organon's low P/E ratio is due to its predicted growth being less than the broader market. Shareholders accept this as they anticipate future earnings won't bring any pleasant surprises. The share price is unlikely to rise significantly soon under these conditions.
Organon & Co.'s (NYSE:OGN) Earnings Are Not Doing Enough For Some Investors 4
Analysts show increased negativity towards the business following recent results, reflected in a minor decrease in next year's EPS estimates. Despite predicted earnings decline, Organon's valuation is not expected to be significantly affected, but growth is anticipated to lag behind the industry.
1
1
Seeking Alpha analysts are growing more bullish on the Merck spinoff, despite Wall Street's neutral stance. Analysts Leo Nelissen and Gen Alpha highlight OGN's attractive yield as a reason for their Buy ratings.
1
Despite the company's payout ratio not posing an immediate concern, the significant decline in earnings per share raises concerns about Organon from a dividend perspective. Therefore, caution is advised for potential investors considering Organon for its upcoming dividend.
2
Read more